Drug intelligence / Profile preview

R228060

Development stage: Unknown
Lead developer: Jazz Pharmaceuticals
Administration: Oral

Overview

R228060 is an investigational drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. It is currently undergoing a 6-week, randomized, double-blind, parallel-group, active- and placebo-controlled clinical trial to assess its efficacy in adult subjects with moderately to severely depressed Major Depressive Disorder (MDD).

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on R228060.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R228060.

Explore the full profile